Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Process for preparing compound coemzyme medicine and its compound coemzyme medicine and clinical use

A technology of coenzyme and yeast cells, applied in the field of medicine, can solve the problems of the scope of influence, inactivation of coenzyme, degradation and destruction, etc.

Active Publication Date: 2005-03-02
北京奥路特生物医药研发有限公司 +2
View PDF0 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, because the original production process used old production processes such as heating to break the wall, vacuum decompression concentration, dialysis, etc., it resulted in the inactivation and degradation of various coenzymes, thus affecting the range of coenzymes and clinical applications.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for preparing compound coemzyme medicine and its compound coemzyme medicine and clinical use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Fresh baker’s yeast is added with 5 times PH4.0 0.01M acetic acid buffer solution to make yeast cell suspension; use a high-pressure homogenizer to break the yeast cells at a pressure of 100Mpa to maintain the cell suspension below 20°C; the broken yeast is under 5°C The cell suspension was centrifuged in freezing and centrifuged at a speed of 20000 CPM for 60 minutes to obtain a clear solution; adsorbed on activated carbon, desorbed with a 40% ammonia ethanol solution containing 2% ammonia, adjusted to pH 8.0 with the desorbed solution, and applied to Ambrite IRC50 ion exchange column with pH 8.5 , 0.02M phosphoric acid solution for elution; the eluate is ultrafiltered with an ultrafilter with a cut-off molecular weight of 8000, and the filtrate is concentrated by nanofiltration to remove H 2 O, concentrate to 1 / 10 of the original volume, adjust the pH to 3.5, add 5 times the volume, precipitate with cold acetone at -10°C, collect the precipitate, dissolve in pyrogen-free ...

Embodiment 2

[0023] Add 6 times PH3.0, 0.03M acetic acid buffer to fresh brewer's yeast, crush the cells with a high-pressure homogenizer at 70Mpa pressure, maintain the cell crushing liquid below 10°C, centrifuge at 30000 CPM for 45 minutes at 3°C ​​to obtain a clear liquid; Ultrafiltration with an ultrafiltration membrane with a molecular weight cut-off of 8000; activated carbon adsorption, analysis with 40% ammonia ethanol containing 3.0% ammonia; pH of the analysis solution adjusted to 7.5 on Ambrite IRC 50 ion exchange column, with pH 9.0, 0.01M phosphate buffer Elution; the eluate is ultrafiltered through an ultrafiltration membrane with a cutoff molecular weight of 5000; the ultrafiltrate is removed by reverse osmosis 2 O was concentrated to 1 / 5 of the original volume, adjusted to pH 2.5, added 10 times the volume of cold acetone at -15°C, overnight at 0°C, and collected the precipitate the next day. The precipitate is dissolved in pyrogen-free water, the concentration of each component...

Embodiment 3

[0026] Add 8 times the pH4.5, 0.01M acetic acid buffer solution to the fresh edible yeast; use a high-pressure homogenizer to break the yeast cells under a pressure of 150Mpa to maintain the broken solution below 5°C; centrifuge at 35000cpm at 0°C for 30 minutes Obtain the clear liquid; collect the filtrate; the activated carbon absorbs the filtrate and analyzes it with 40% ethanol containing 3.5% ammonia; adjusts the pH of the analysis solution to 9.0, and applies the Ambrite IRC 50 ion exchange column to pH8.0, 0.03M phosphate buffer The eluate is eluted by an ultrafiltration membrane with a cutoff molecular weight of 9000. The ultrafiltrate is concentrated to 1 / 8 of the original volume by reverse osmosis, adjusted to pH 3.0, and added 8 times the volume of cold acetone at -20°C. Collect the precipitate every day. The precipitate is dissolved in pyrogen-free water, the concentration of each component is measured, sterilized, potted, and lyophilized.

[0027] Coenzyme ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention belongs to the field of medicine technology. The compound coenzyme medicine contains CoA, NAD, GSH and ATP; and features that it contains also FMN, FAD, ADP, AMP and SAM. The present invention has improved compound coenzyme medicine preparing process. The compound coenzyme medicine can protect liver cell, myocardial cell and other cells, maintain or restore their normal metabolism, and may be used in heart and liver surgical operation, restoring of damaged liver, restoring damaged cell caused by radiotherapy and chemotherapy.

Description

Technical field [0001] The invention belongs to the technical field of medicine, and particularly relates to a new preparation method of a composite coenzyme drug and a new type of composite coenzyme drug and new clinical applications. Background technique [0002] In the 1970s, a composite coenzyme freeze-dried powder injection for injection was developed. It is extracted from yeast (saccharomyces cerevisiae, edible yeast and Geotrichum candidum) and contains coenzyme A (CoA), coenzyme I (NAD), ATP and The natural coenzyme compound preparation of glutathione. It has been used for the treatment of acute and chronic hepatitis, primary thrombocytopenic purpura, thrombocytopenia for a long time, and can be used as adjuvant therapy for coronary atherosclerosis, chronic arteritis, myocardial infarction, oliguria and uremia caused by renal failure. [0003] Yeast is a single-celled eukaryotic organism, and its cells contain various coenzymes necessary for the metabolism (synthesis and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/06A61P1/16A61P7/04A61P9/10A61P13/12A61P31/12A61P39/02A61P43/00
Inventor 郑昌学
Owner 北京奥路特生物医药研发有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com